Dihydromyricetin alleviates intestinal inflammation by changing intestinal microbial metabolites and inhibiting the expression of the MyD88/NF-κB signaling pathway

Chaoyu Wen, Fan Zhang, Kang Yang, Sufang Han, Shiyan Jian, Baichuan Deng
{"title":"Dihydromyricetin alleviates intestinal inflammation by changing intestinal microbial metabolites and inhibiting the expression of the MyD88/NF-κB signaling pathway","authors":"Chaoyu Wen,&nbsp;Fan Zhang,&nbsp;Kang Yang,&nbsp;Sufang Han,&nbsp;Shiyan Jian,&nbsp;Baichuan Deng","doi":"10.1002/aro2.21","DOIUrl":null,"url":null,"abstract":"<p>Inflammatory bowel disease (IBD), a common chronic gastrointestinal disease in humans, has emerged as a global public health challenge. Dihydromyricetin (DHM) has anti-inflammatory and antioxidant activities, which can alleviate inflammation. In this study, we explored the effect and underlying mechanism of DHM on dextran sulfate sodium (DSS)-induced colitis in mice and porcine jejunum epithelial cells (IPEC-J2) exposed to lipopolysaccharide (LPS). We found that DHM alleviated loss of weight, diarrhea, and damage of colon structure in colitis mice. For the intestinal microbial, a significant rise in the amount of the potentially beneficial genera and a decline in the amount of harmful genera were observed in DHM-treated colitis mice. Metabolomic analysis of cecal content revealed that DHM restored phenylalanine metabolism, arginine biosynthesis, and arachidonic acid metabolism disorders caused by intestinal inflammation. Moreover, DHM decreased the level of pro-inflammatory cytokines and reactive oxygen species in LPS-treated IPEC-J2 cells. DHM also reduced the expression of MyD88 and nuclear factor-κB (NF-κB). In summary, we found that 125 mg/kg DHM administration alleviated diarrhea, reinstated intestinal barrier function, modulated intestinal dysbiosis, and suppressed the expression of myeloid differentiation factor 88 (MyD88) and NF-κB. Therefore, DHM may be a potentially therapeutic agent for IBD.</p>","PeriodicalId":100086,"journal":{"name":"Animal Research and One Health","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/aro2.21","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Animal Research and One Health","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/aro2.21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Inflammatory bowel disease (IBD), a common chronic gastrointestinal disease in humans, has emerged as a global public health challenge. Dihydromyricetin (DHM) has anti-inflammatory and antioxidant activities, which can alleviate inflammation. In this study, we explored the effect and underlying mechanism of DHM on dextran sulfate sodium (DSS)-induced colitis in mice and porcine jejunum epithelial cells (IPEC-J2) exposed to lipopolysaccharide (LPS). We found that DHM alleviated loss of weight, diarrhea, and damage of colon structure in colitis mice. For the intestinal microbial, a significant rise in the amount of the potentially beneficial genera and a decline in the amount of harmful genera were observed in DHM-treated colitis mice. Metabolomic analysis of cecal content revealed that DHM restored phenylalanine metabolism, arginine biosynthesis, and arachidonic acid metabolism disorders caused by intestinal inflammation. Moreover, DHM decreased the level of pro-inflammatory cytokines and reactive oxygen species in LPS-treated IPEC-J2 cells. DHM also reduced the expression of MyD88 and nuclear factor-κB (NF-κB). In summary, we found that 125 mg/kg DHM administration alleviated diarrhea, reinstated intestinal barrier function, modulated intestinal dysbiosis, and suppressed the expression of myeloid differentiation factor 88 (MyD88) and NF-κB. Therefore, DHM may be a potentially therapeutic agent for IBD.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
二氢杨梅素通过改变肠道微生物代谢物和抑制MyD88/NF‐κB信号通路的表达来缓解肠道炎症
炎症性肠病(IBD)是人类常见的慢性胃肠道疾病,已成为全球公共卫生挑战。二氢杨梅素(DHM)具有抗炎和抗氧化活性,可以减轻炎症。在这项研究中,我们探讨了DHM对暴露于脂多糖(LPS)的小鼠和猪空肠上皮细胞(IPEC - J2)诱导的小鼠结肠炎的影响及其潜在机制。我们发现DHM减轻了结肠炎小鼠的体重减轻、腹泻和结肠结构损伤。对于肠道微生物,在DHM治疗的结肠炎小鼠中,观察到潜在有益菌的数量显著增加,有害菌的数量下降。盲肠内容物代谢组学分析显示,DHM可恢复肠道炎症引起的苯丙氨酸代谢、精氨酸生物合成和花生四烯酸代谢紊乱。此外,DHM降低了LPS处理的IPEC - J2细胞的促炎细胞因子和活性氧水平。DHM还能降低MyD88和核因子κB (NF - κB)的表达。综上所述,我们发现125 mg/kg DHM可以缓解腹泻,恢复肠道屏障功能,调节肠道生态失调,抑制髓样分化因子88 (MyD88)和NF - κB的表达。因此,DHM可能是一种潜在的IBD治疗剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Issue Information Temperature and humidity as drivers for the transmission of zoonotic diseases Free iron accumulation and oxidative stress burden induce ferroptotic atrophy of chicken yolk sac during the late embryogenesis Selection of the most informative wavenumbers to improve prediction accuracy of milk fatty acid profile based on milk mid‐infrared spectra data Functional roles of folic acid in alleviating dexamethasone‐induced fatty liver syndrome in laying hens
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1